Safety issues and concerns of new immunomodulators in rheumatology

Expert Opinion on Drug Safety

Volumn 14, Issue 3, 2015, Pages 389-399

  Selmi, Carlo ^a,b   Ceribelli, Angela ^a,b   Naguwa, Stanley M ^c   Cantarini, Luca ^d   Shoenfeld, Yehuda ^e  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SIENA   (Italy)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

Adverse event; Biologic registry; Cancer; Infection; TNF inhibitor

Indexed keywords

AUTOANTIBODY; IMMUNOMODULATING AGENT; ANTIRHEUMATIC AGENT; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL INFECTION; CANCER RISK; CARDIOVASCULAR DISEASE; DRUG SAFETY; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION; INFECTION RISK; INJECTION SITE REACTION; LABORATORY TEST; MEDICAL HISTORY; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; PARASITOSIS; REVIEW; RHEUMATOLOGY; SOLID TUMOR; SURGICAL INFECTION; TUBERCULOSIS; VACCINATION; VIRUS INFECTION; VIRUS REACTIVATION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; PROCEDURES;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; IMMUNOLOGIC FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923319847     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.993605     Document Type: Review

References (97)

1. Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol 2011;7(11):639-52
2. Mrozek N, Pereira B, Soubrier M, et al. Screening of tuberculosis before biologics. Med Mal Infect 2012;42(1):1-4
3. Lin PL, Plessner HL, Voitenok NN, et al. Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc 2007;12(1):22-5
4. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36(5):1185-206
5. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with antitumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60(7):1884-94
6. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73(3):529-35
7. Mazurek G.H, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERONTB gold test for detecting mycobacterium tuberculosis infection, united states. MMWR Recomm Rep 2005;54(RR-15):49-55
8. Lighter J, Rigaud M, Eduardo R, et al. Latent tuberculosis diagnosis in children by using the QuantiFERON-TB gold intube test. Pediatrics 2009;123(1):30-7
9. Sahni R, Miranda C, Yen-Lieberman B, et al. Does the implementation of an interferon-gamma release assay in lieu of a tuberculin skin test increase acceptance of preventive therapy for latent tuberculosis among healthcare workers? Infect Control Hosp Epidemiol 2009;30(2):197-9
10. Marra F, Marra CA, Sadatsafavi M, et al. Cost-effectiveness of a new interferonbased blood assay, QuantiFERON-TB gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis 2008;12(12):1414-24
11. Mazurek G.H, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection United States, 2010. MMWR Recomm Rep 2010;59(RR-5):1-25
12. Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-alpha) targeted biologics and recently licensed TNF-alpha inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 2014;91:56-64
13. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341(1):22-6
14. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49(5 Suppl):S156-65
15. Lunel-Fabiani F, Masson C, Ducancelle A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine 2014. [Epub ahead of print]
16. Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8(6):348-57
17. Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2011;70(10):1719-25
18. European association for the study of the liver. EASL Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50(2):227-42
19. Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009;36(6):1188-94
20. Ferri C, Sebastiani M, Antonelli A, et al. Current treatment of hepatitis Cassociated rheumatic diseases. Arthritis Res Ther 2012;14(3):215
21. Brunasso AM, Puntoni M, Gulia A, et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011;50(9):1700-11
22. Saag KG, Teng GG, Patkar NM, et al. American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59(6):762-84
23. Abdelmalek MF, Liu C, Valentine JF. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with crohn's disease. Am J Gastroenterol 2007;102(6):1333-4
24. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatmentnaive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42(3):315-22
25. Sagnelli E, Pisaturo M, Sagnelli C, et al. Rituximab-based treatment, HCV replication, and hepatic flares. Clin Dev Immunol 2012;2012:945950
26. Cobo-Ibanez T, Descalzo MÁ , Loza-Santamaría E, et al. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti TNF or rituximab: data from the spanish registry Biobadaser 2.0. Rheumatol Int 2014;34(7):953-61
27. Fessler BJ. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 2002;16(2):281-91
28. Chen IJ, Tsai WP, Wu YJ, et al. Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology (Oxford) 2010;49(12):2429-37
29. Ruiz-Irastorza G, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009;11(4):R109
30. Diaz-Lagares C, Olivares N, Ruiz-Arruza I, et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther 2011;13(4):R112
31. Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012;12(2):225-9
32. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46(9):2294-300
33. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62(9):2625-32
34. Calabrese LH, Molloy ES, Huang D, et al. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007;56(7):2116-28
35. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009;60(12):3761-5
36. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012;64(9):3043-51
37. Berger JR. Progressive multifocal leukoencephalopathy. Handb Clin Neurol 2014;123:357-76
38. Palazzo E, Yahia SA. Progressive multifocal leukoencephalopathy in autoimmune diseases. Joint Bone Spine 2012;79(4):351-5
39. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford) 2012;51(Suppl 6):vi37-43
40. Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol 2012;3:388
41. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85
42. Saillot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009;68(1):25-32
43. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;16(2):CD008794
44. Galloway JB, Hyrich KL, Mercer LK, et al. The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2011;50(7):1341-2
45. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the corrona registry. Ann Rheum Dis 2010;69(2):380-6
46. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306(21):2331-9
47. Grijalva CG, Kaltenbach L, Arbogast PG, et al. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) 2010;49(1):82-90
48. Komano Y, Tanaka M, Nanki T, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the registry of japanese rheumatoid arthritis patients for longterm safety. J Rheumatol 2011;38(7):1258-64
49. Sakai R, Komano Y, Tanaka M, et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64(8):1125-34
50. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70(11):1914-20
51. Lane MA, McDonald JR, Zeringue AL, et al. TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore) 2011;90(2):139-45
52. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301(7):737-44
53. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009;48(10):1364-71
54. Garcia-Doval I, Pérez-Zafrilla B, Descalzo MA, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010;69(10):1751-5
55. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309(9):887-95
56. Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J Eur Acad Dermatol Venereol 2014;28(7):846-52
57. Umekita K, Hidaka T, Miyauchi S, et al. Treatment with anti-tumor necrosis factor biologic agents in human T lymphotropic virus type I-positive patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66(5):788-92
58. Sellam J, Bouvard B, Masson C, et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine 2007;74(2):197-200
59. Bartke U, Venten I, Kreuter A, et al. Human immunodeficiency virusassociated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol 2004;150(4):784-6
60. Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatol 2003;30(2):407-11
61. Linardaki G, Katsarou O, Ioannidou P, et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007;34(6):1353-5
62. Aboulafia DM, Bundow D, Wilske K, et al. Etanercept for the treatment of human immunodeficiency virusassociated psoriatic arthritis. Mayo Clin Proc 2000;75(10):1093-8
63. Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008;67(5):710-12
64. Achenza MI, Selmi C. Autoimmunity and cancer. Asian Pac J Cancer Prev 2012(13 Suppl):29-40
65. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54(3):692-701
66. Andersen CL, Lindegaard H, Vestergaard H, et al. Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting. PLoS One 2014;9(6):e99388
67. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(9):2757-64
68. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the swedish biologics register. Ann Rheum Dis 2009;68(5):648-53
69. Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009;48(3):386-8
70. Amari W, Zeringue AL, McDonald JR, et al. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 2011;50(8):1431-9
71. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70(11):1895-904
72. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13(5):R141
73. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 5):v38-47
74. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and anti-drug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2014. [Epub ahead of print]
75. Wang SL, Hauenstein S, Ohrmund L, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal 2013;78-79-39-44
76. Molnar T, Farkas K, Nyári T, et al. Frequency and predictors of loss of response to infliximab or adalimumab in crohn's disease after one-year treatment period - a single center experience. J Gastrointestin Liver Dis 2012;21(3):265-9
77. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012;382(1-2):177-88
78. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105(5):1133-9
79. Ali T, Yun L, Rubin DT. Risk of postoperative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol 2012;18(3):197-204
80. Aeschlimann FA, Hofer K, Schneider EC, et al. A5: detectable antiinfliximab antibodies in children treated with infliximab for rheumatic diseases. Arthritis Rheumatol 2014;66(Suppl 11):S7
81. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a french national survey. Arthritis Res Ther 2005;7(3):R545-51
82. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003;22(1):56-61
83. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59(7):996-1001
84. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143(2):223-31
85. English PL, Vender R. Occurrence of plantar pustular psoriasis during treatment with infliximab. J Cutan Med Surg 2009;13(1):40-2
86. Ramos-Casals M, Brito-Zerón P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86(4):242-51
87. Srivastava MD, Alexander F, Tuthill RJ. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 2005;61(4):329-36
88. Phillips K, Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum 2005;53(4):618-20
89. Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis 2010;69(9):1691-3
90. Hauser SL, Waubant E, Arnold D, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88
91. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003;107(25):3133-40
92. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109(13):1594-602
93. Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012;379(9822):1214-24
94. Falagas ME, Manta KG, Betsi GI, et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 2007;26(5):663-70
95. Brydak LB, Roszkowska-Blaim M, Machala M, et al. Antibody response to influenza immunization in two consecutive epidemic seasons in patients with renal diseases. Vaccine 2000;18(28):3280-6
96. Chalmers A, Scheifele D, Patterson C, et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994;21(7):1203-6
97. Ferreira I, Isenberg D. Vaccines and biologics. Ann Rheum Dis 2014;73(8):1446-54